Anti-TRAF6 antibody [EP592Y],Abcam,AB40675
What is this antibody validated in? Anti-TRAF6 antibody [EP592Y] (ab40675) is a rabbit recombinant monoclonal antibody and is validated for use in Western Blot (WB), Immunohistochemistry (IHC-P), Immunocytochemistry/immunofluorescence (ICC/IF) in Human, Mouse, Rat samples. What is the molecular weight of TRAF6? Anti-TRAF6 [EP592Y] (ab40675) specifically detects a band for TRAF6 (UniProt: Q9Y4K3) at a molecular weight of 63kDa. Trusted by the scientific community Anti-TRAF6 [EP592Y] (ab40675) was first used in a scientific publication in 2006 and has been cited over 40 times in peer-reviewed journals. Trial sizes available! Test your antibody or perform pre-screening before committing to a larger quantity. Sold in 10µl. Discover our selection of trial-size antibodies. Specificity confirmed The specificity of Anti-TRAF6 antibody [EP592Y] (ab40675) has been confirmed by Western blot testing in TRAF6 Knockout HAP1 cells. Other related products We have a range of other formats of antibody clone [EP592Y] also available for your convenience: ab40675, Carrier free - ab227560 Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .
Host
Rabbit
Reactivity
Mouse, Rat, Human
Application
WB, IHC-P, ICC/IF
Platform ID
BAB811810817
Abcam
Contact
Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215
Email:
Specifications
Scientific Background
Target data E3 ubiquitin ligase that, together with UBE2N and UBE2V1, mediates the synthesis of 'Lys-63'-linked-polyubiquitin chains conjugated to proteins, such as ECSIT, IKBKG, IRAK1, AKT1 and AKT2 (PubMed : 11057907, PubMed : 18347055, PubMed : 19465916, PubMed : 19713527, PubMed : 31620128). Also mediates ubiquitination of free/unanchored polyubiquitin chain that leads to MAP3K7 activation (PubMed : 19675569). Leads to the activation of NF-kappa-B and JUN (PubMed : 16378096, PubMed : 17135271, PubMed : 17703191). Seems to also play a role in dendritic cells (DCs) maturation and/or activation (By similarity). Represses c-Myb-mediated transactivation, in B-lymphocytes (PubMed : 18093978, PubMed : 18758450). Adapter protein that seems to play a role in signal transduction initiated via TNF receptor, IL-1 receptor and IL-17 receptor (PubMed : 12140561, PubMed : 19825828, PubMed : 8837778). Regulates osteoclast differentiation by mediating the activation of adapter protein complex 1 (AP-1) and NF-kappa-B, in response to RANK-L stimulation (By similarity). Together with MAP3K8, mediates CD40 signals that activate ERK in B-cells and macrophages, and thus may play a role in the regulation of immunoglobulin production (By similarity). Participates also in the TCR signaling by ubiquitinating LAT (PubMed : 23514740, PubMed : 25907557). See full target information TRAF6
Category Paths
- Products>Primary Antibodies>Monoclonal Antibodies
- Products>Primary Antibodies>IHC Antibodies
- Products>Primary Antibodies>Recombinant Antibodies
- Products>Trial Size Antibodies
Please provide the required information below so that we can quickly source your products.